Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.
Researchers at Stanford have developed gene editing methods for modifying hematopoietic stem and progenitor cells (HSPCs) to express truncated forms of the erythropoietin receptor (tEPOR).
Stanford inventors have developed technologies for improved islet transplantation using a bioscaffold platform that maintains islet health during and after their transplantation.
Stanford inventors have developed technologies for improved islet transplantation using a bioscaffold platform that maintains islet health during and after their transplantation.
To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.
Despite their rapidly expanding therapeutic potential, human pluripotent stem cell (hPSC)-derived cell therapies continue to have serious safety risks.
Researchers at Stanford have developed chemically defined, polyvinyl alcohol (PVA)-based media for culturing hematopoietic stem cells and immune cells (e.g., T cells).
Stanford researchers have proposed the use of a conductive graphene scaffold (CGS) as a biocompatible scaffold for growth of neural tissues. The high conductivity enables the use of electrical stimulation to control the development of induced pluripotent stem cells (iPSCs).
A team of Stanford scientists have developed a technique to rapidly convert adult somatic cells directly into functional neuronal cells without the intermediate step of generating iPS cells (induced pluripotent stem cells).
Researchers in Prof. Irving Weissman's lab have developed and patented antibodies and methods to prevent the formation of teratomas from human pluripotent stem cells used for regenerative medicine, cell therapy or research.